Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

16

Revenue 2017

Shire

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Shire's 2013 CNS, immunology and metabolic's sales performance.

Shire

Spark sputters on haemophilia A gene therapy safety scare

Spark sputters on haemophilia A gene therapy safety scare Biosciences and Shire.

Immunology keeps Shire figures solid as Takeda takeover nears

Immunology keeps Shire figures solid as Takeda takeover nears acquisition target Shire – and on the whole the UK-listed firm didn’t disappoint. ... However, Shire’s drugs for haemophilia patients with inhibitors such as Feiba came under competitive pressure from the likes of Roche’s recently-approved

NHS England says yes to Roche's Hemlibra

NHS England says yes to Roche's Hemlibra Among the treatments and interventions listed in the latest review at 'Level 2' were Shire’s Obizur (susoctocog alfa) for patients with acquired haemophilia A (a rare form of the disease)

Daily Brief: Resignation throws Brexit into disarray, Celgene exec joins Orchard board, Scotland rules on EUSA drug

Daily Brief: Resignation throws Brexit into disarray, Celgene exec joins Orchard board, Scotland rules on EUSA drug therapies.”. Prior to Celgene, Dr. Beck was senior vice president of pharmaceutical development at Shire from 2012 to 2016.

Daily Brief: Crunch time for Brexit, GSK CEO RSVP from Trump

Daily Brief: Crunch time for Brexit, GSK CEO RSVP from Trump Takeda to sell Osaka HQ to help cover Shire costs. Takeda’s $63bn purchase of Shire is the biggest pharma merger for some years, and the Japanese pharma company is making

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...

Infographics